[go: up one dir, main page]

WO2000075157A1 - Synthese d'oligonucleotides utilisant des acides de lewis comme activateurs - Google Patents

Synthese d'oligonucleotides utilisant des acides de lewis comme activateurs Download PDF

Info

Publication number
WO2000075157A1
WO2000075157A1 PCT/US2000/012530 US0012530W WO0075157A1 WO 2000075157 A1 WO2000075157 A1 WO 2000075157A1 US 0012530 W US0012530 W US 0012530W WO 0075157 A1 WO0075157 A1 WO 0075157A1
Authority
WO
WIPO (PCT)
Prior art keywords
group
chloride
composition according
alkoxy
magnesium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2000/012530
Other languages
English (en)
Inventor
Xiu C. Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Laboratories
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Priority to CA002376016A priority Critical patent/CA2376016A1/fr
Priority to MXPA01012444A priority patent/MXPA01012444A/es
Priority to EP00926516A priority patent/EP1181301A1/fr
Priority to JP2001502438A priority patent/JP2003514766A/ja
Publication of WO2000075157A1 publication Critical patent/WO2000075157A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids

Definitions

  • the present invention relates to a process utilizing Lewis acids as activators in the preparation of oligonucleotides by phosphoramidite chemistry.
  • the present invention relates generally to the fields of organic chemistry and biology.
  • the present invention is directed to compositions and methods for use in oligonucleotide synthesis.
  • Phosphoramidite chemistry (Beaucage, S. L., and Lyer, R. P. Tetrahedron (1992), 48, 2223-2311) has become by far the most widely used coupling chemistry for the synthesis of oligonucleotides.
  • phosphoramidite synthesis of oligonucleotides involves activation of nucleoside phosphoramidite monomer precursors by reaction with an activating agent to form activated intermediates, followed by sequential addition of the activated intermediates to the growing oligonucleotide chain (generally anchored at one end to a suitable solid support) to form the oligonucleotide product.
  • Tetrazole is commonly used for the activation of the nucleoside phosphoramidite monomers; the activation occurs by the mechanism depicted in Scheme I.
  • Tetrazole has an acidic proton which presumably protonates the basic nitrogen of the diisopropylamino phosphine group, thus making the diisopropylamino group a leaving group.
  • the negatively charged tetrazolium ion then makes an attack on the trivalent phosphorous, forming a transient phosphorous tetrazolide species.
  • the 5'-OH group of the solid support bound nucleoside then attacks the active trivalent phosphorous species, resulting in the formation of the internucleotide linkage.
  • tetrazole Principal drawbacks of tetrazole are its cost and instability which includes its potential to explode (Material Safety Data Sheets or MSDS lists IH-tetrazole as a severe explosion hazard). Because of its inherent instability, sublimed tetrazole is generally required to ensure desired coupling yields. Further, tetrazole (which is typically used near its saturated solubility of 0.5M) tends to precipitate out of acetonitrile solution at cold temperatures; this can lead to valve blockage on some automated DNA synthesizers. Other activators which work almost as efficiently as tetrazole have similar drawbacks to those of tetrazole as discussed above.
  • activators which are all proton donors, include the following members of the tetrazole class of activators: 5-(p- nitrophenyl) tetrazole (Froehler, B. C. and Mattcucci, M. D., Tetrahedron Letters (1983), 24, 3171-3174); 5-(p-nitrophenyl) tetrazole and DMAP (Pon, R.T., Tetrahedron Letters (1987), 28, 3643-3646); and 5-(ethylthio)- IH-tetrazole (Wright, P. et al., Tetrahedron
  • a 1 :1 mixture of benzimidazole and BF 3 etherate is disclosed wherein the BF 3 component acts to increase the acidity of the benzimidazole proton necessary for activation of the phosphoramidite (intermediates).
  • the benzimidazole BF 3 complex acts in a manner similar to tetrazole described in Scheme 1.
  • the present invention does not activate phosphoramidite intermediates with a proton donor but instead utilizes Lewis acids for activation.
  • BF 3 etherate is used in the present invention.
  • the advantages of BF 3 etherate over the benzimidazole BF 3 complex include commercial availability and ease of removal of diethyl ether versus removal of benzimidazole.
  • the activated phosphoramidite intermediates are highly sensitive to moisture. An excess of 50% to 100% of the highly valuable phosphoramidites are required for sequencing even with anhydrous solvents ( ⁇ 20 ppm moisture content). The presence of trace amounts of moisture results in considerable loss of yield and an increase in deleted sequencing impurities.
  • Lewis acids can act as moisture scavengers minimizing decomposition of the phosphoramidite. Therefore, the use of Lewis acids for activation of phosphoramidite intermediates leads to improved coupling efficiency, lower cost, and convenient material handling and operation.
  • B 1 is selected from the group consisting of a purine base and a pyrimidine base;
  • R 1 is a secondary amine, a preferred amine is diisopropylamine;
  • R 2 is selected from the group consisting of alkoxy, alkyl, alkylsulfonylalkoxy arylsulfonylalkoxy, cyanoalkoxy, and haloalkoxy;
  • R 3 is a hydroxy-protecting group, a preferred group is 4-4'-dimethoxytrityl
  • R 4 is selected from the group consisting of hydrogen and -OR 7 wherein, R 7 is a hydroxy- protecting group; comprising treating the phosphoramidite monomers of formula I with an optional amount of pyridine and a Lewis acid, preferred Lewis acids are selected from aluminum chloride, bismuth(III) chloride, boron trifluoride, iron(II) chloride, iron(III) chloride, magnesium bromide, magnesium chloride, magnesium trifluoromethanesulfonate, manganese(II) chloride, zinc bromide, zinc chloride and zirconium(IN) chloride.
  • preferred Lewis acids are selected from aluminum chloride, bismuth(III) chloride, boron trifluoride, iron(II) chloride, iron(III) chloride, magnesium bromide, magnesium chloride, magnesium trifluoromethanesulfonate, manganese(II) chloride, zinc bromide, zinc chloride and zirconium(IN) chloride.
  • alkoxy refers to an alkyl group, as defined herein, appended to the parent molecular moiety through an oxy group, as defined herein.
  • alkoxy include, but are not limited to, methoxy, ethoxy, propoxy, 2-propoxy, butoxy, tert-butoxy, pentyloxy, and the like.
  • alkyl refers to a straight or branched chain hydrocarbon containing from 1 to 5 carbon atoms.
  • Representative examples of alkyl include, but are not limited to, methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl, iso-butyl, tert-butyl, n-pentyl, and the like.
  • alkylcarbonyl refers to an alkyl group, as defined herein, appended to the parent molecular moiety through a carbonyl group, as defined herein.
  • Representative examples of alkylcarbonyl include, but are not limited to, acetyl, ethylcarbonyl, and the like.
  • alkylcarbonyloxy refers to an alkylcarbonyl group, as defined herein, appended to the parent molecular moiety through an oxy group, as defined herein.
  • Representative examples of alkylcarbonyloxy include, but are not limited to, acetyloxy, ethylcarbonyloxy, t-butylcarbonyloxy, and the like.
  • alkylsulfonyl refers to an alkyl group, as defined herein, appended to the parent molecular moiety through a sulfonyl group, as defined herein.
  • Representative examples of alkylsulfonyl include, but are not limited to, methylsulfonyl, ethylsulfonyl, and the like.
  • alkylsulfonylalkoxy refers to an alkylsulfonyl group, as defined herein, appended to the parent molecular moiety through an alkoxy group, as defined herein.
  • Representative examples of alkylsulfonylalkoxy include, but are not limited to, 2-methylsulfonylethoxy, 2-ethylsulfonylethoxy, and the like.
  • amino refers to a -NH 2 group.
  • amino-protecting group or “N-protecting group,” refer to groups intended to protect an amino group against undersirable reactions during synthetic procedures. Commonly used nitrogen-protecting groups are disclosed in Greene, T. W., &
  • nitrogen-protecting groups are formyl, acetyl, benzoyl, pivaloyl, t-butylacetyl, phenylsulfonyl, benzyl, t-butyloxycarbonyl (Boc), and benzyloxycarbonyl (Cbz).
  • aryl refers to an aromatic monocyclic ring system, or a bicyclic-fused ring system wherein one or both of the fused rings are aromatic.
  • aryl include, but are not limited to, azulene, indanyl, indenyl, naphthyl, phenyl, tetrahydronaphthyl, and the like.
  • the aryl groups of this invention can be substituted with 1, 2, or 3 substituents independently selected from alkyl, cyano, halogen, haloalkyl, and nitro.
  • arylalkoxy refers to an aryl group, as defined herein, appended to the parent molecular moiety through an alkoxy group, as defined herein.
  • arylalkoxy include, but are not limited to, 2-phenylethoxy, 2-naphthylethoxy, 2-(4-nitrophenyl)ethoxy, and the like.
  • arylsulfonyl refers to an aryl group, as defined herein, appended to the parent molecular moiety through a sulfonyl group, as defined herein.
  • arylsulfonyl include, but are not limited to, phenylsulfonyl, naphthylsulfonyl, and the like.
  • arylsulfonylalkoxy refers to an arylsulfonyl group, as defined herein, appended to the parent molecular moiety through an alkoxy group, as defined herein.
  • Representative examples of arylsulfonylalkoxy include, but are not limited to, 2-phenylsulfonylethoxy, 3-phenylsulfonylpropoxy, and the like.
  • carbonyl refers to a -C(O)- group.
  • catechol refers to a C 6 H 4 - 1 ,2-(O-) 2 group, wherein both oxygen atoms are attached to M, as defined herein.
  • cyano refers to a -CN group.
  • cyanoalkoxy refers to a cyano group, as defined herein, appended to the parent molecular moiety through an alkoxy group, as defined herein.
  • Representative examples of cyanoalkoxy include, but are not limited to, 2-cyanoethoxy, 3-cyanopropoxy, 1 -methyl-2-cyanoethoxy, l,l-dimethyl-2-cyanoethoxy, and the like.
  • halo refers to -Cl, -Br, -I or -F.
  • haloalkoxy refers to at least one halogen, as defined herein, appended to the parent molecular moiety through an alkoxy group, as defined herein. Representative examples of haloalkoxy include, but are not limited to, 2,2,2- trichloroethoxy, l,l-dimethyl-2,2,2-trichloroethoxy, trifluoromethoxy, and the like.
  • haloalkyl refers to at least one halogen, as defined herein, appended to the parent molecular moiety through an alkyl group, as defined herein.
  • Representative examples of haloalkyl include, but are not limited to, chloromethyl, 2- fluoroethyl, trifiuoromethyl, pentafluoroethyl, 2-chloro-3-fluoropentyl, and the like.
  • hydroxy-protecting group or "O-protecting group” refers to groups intended to protect a hydroxy group against undesirable reactions during synthetic procedures. Commonly used hydroxy-protecting groups are disclosed in T.H. Greene and P.G.M. Wuts, Protective Groups in Organic Synthesis. 2nd edition, John Wiley & Sons, New York (1991), which is hereby incorporated by reference.
  • hydroxy- protecting groups include, but are not limited to, substituted methyl ethers, for example, methoxymethyl, benzyloxymethyl, 2-methoxyethoxymethyl, 2-(trimethylsilyl)- ethoxymethyl, benzyl, and triphenylmethyl; tetrahydropyranyl ethers; substituted ethyl ethers, for example, 2,2,2-trichloroethyl and t-butyl; silyl ethers, for example, trimethylsilyl, t-butyldimethylsilyl and t-butyldiphenylsilyl; cyclic acetals and ketals, for example, methylene acetal, acetonide and benzylidene acetal; cyclic ortho esters, for example, methoxymethylene; cyclic carbonates; cyclic boronates; carbonyl derivatives, for example, acetyl, p-phenylazopheny
  • Lewis acid refers to a chemical species, other than a proton, that has a vacant orbital or accepts an electron pair. It is to be understood that Lewis acids can be purchased or prepared as complexes including but not limited to, etherates, hydrates, and thioetherates. It is to be further understood that complexes purchased or prepared for the present invention do not contain an acidic proton.
  • Lewis acid examples include, but are not limited to, aluminum chloride, bismuth(III) chloride, boron trifluoride, iron(II) chloride, iron(III) chloride, magnesium bromide, magnesium chloride, magnesium trifluoromethanesulfonate, manganese(II) chloride, zinc bromide, zinc chloride, zirconium(IV) chloride, and the like.
  • methylenedioxy refers to a -OC(R 80 )(R 81 )O- group wherein R 80 and R 81 are independently selected from hydrogen and alkyl. The oxygen atoms of the methylenedioxy group are attached to the parent molecular moiety through two adjacent carbon atoms.
  • methylenedioxy group examples include, but are not limited to, 1,3-dioxolanyl, 2,2-dimethyl-l,3-dioxolanyl, 2-methyl-l,3- dioxolanyl, and the like.
  • purine base refers to an organic base selected from 9H-purin-6-ylamine (adenine) and 2-amino-l,9-dihydro-6H-purin-6-one (guanine).
  • adenine 9H-purin-6-ylamine
  • guanine 2-amino-l,9-dihydro-6H-purin-6-one
  • the amino group attached to adenine can be protected with a nitrogen-protecting group.
  • proto refers to H + .
  • pyrimidine base refers to an organic base selected from 2,4(lH,3H)-pyrimidinedione (uracil), 5-methyl-2,4(lH,3H)-pyrimidinedione (thymine), and 4-amino-2(lH)-pyrimidinone (cytosine).
  • uracil 2,4(lH,3H)-pyrimidinedione
  • thymine 5-methyl-2,4(lH,3H)-pyrimidinedione
  • cytosine 4-amino-2(lH)-pyrimidinone
  • the amino group attached to cytosine can be protected with a nitrogen-protecting group.
  • sulfonyl refers to a -SO 2 - group.
  • trifluoromethane refers to a -CF 3 group.
  • trifluoromethanesulfonyl refers to a trifluoromethane group, as defined herein, appended to the parent molecular moiety through a sulfonyl group, as defined herein.
  • trifluoromethanesulfonyloxy refers to a trifluoromethanesulfonyl group, as defined herein, appended to the parent molecular moiety through an oxy group, as defined herein.
  • dimer (iii) can be oxidizied using standard conditions know to those of ordinary skill in the art to give the phosphate, (J. Am. Chem. Soc, (1976), 98, 3655-3661).
  • the 5'-OH of the oxidized dimer can be deprotected and treated with a Lewis acid activated phophoramidite monomer to form a trimer. This sequence of steps can be repeated until an oligonucleotide of desired length has been synthesized such that the process of the present invention can be used for preparing oligonucleotides, including solid phase synthesis thereof.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne un procédé permettant d'effectuer la synthèse d'oligonucléotides par chimie des phosphoramidites, l'amélioration consistant à utiliser des acides de Lewis comme activateurs, afin de créer la liaison phosphore-oxygène.
PCT/US2000/012530 1999-06-03 2000-05-08 Synthese d'oligonucleotides utilisant des acides de lewis comme activateurs Ceased WO2000075157A1 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA002376016A CA2376016A1 (fr) 1999-06-03 2000-05-08 Synthese d'oligonucleotides utilisant des acides de lewis comme activateurs
MXPA01012444A MXPA01012444A (es) 1999-06-03 2000-05-08 Sintesis de oligonucleotido con acidos de lewis como activadores.
EP00926516A EP1181301A1 (fr) 1999-06-03 2000-05-08 Synthese d'oligonucleotides utilisant des acides de lewis comme activateurs
JP2001502438A JP2003514766A (ja) 1999-06-03 2000-05-08 活性剤としてルイス酸を用いるオリゴヌクレオチド合成

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32505599A 1999-06-03 1999-06-03
US09/325,055 1999-06-03

Publications (1)

Publication Number Publication Date
WO2000075157A1 true WO2000075157A1 (fr) 2000-12-14

Family

ID=23266253

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/012530 Ceased WO2000075157A1 (fr) 1999-06-03 2000-05-08 Synthese d'oligonucleotides utilisant des acides de lewis comme activateurs

Country Status (5)

Country Link
EP (1) EP1181301A1 (fr)
JP (1) JP2003514766A (fr)
CA (1) CA2376016A1 (fr)
MX (1) MXPA01012444A (fr)
WO (1) WO2000075157A1 (fr)

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107074902A (zh) * 2014-10-29 2017-08-18 吉利德科学公司 制备核糖核苷的方法
US10988498B2 (en) 2009-09-21 2021-04-27 Gilead Sciences, Inc. Processes and intermediates for the preparation of 1′-substituted carba-nucleoside analogs
US11007208B2 (en) 2015-09-16 2021-05-18 Gilead Sciences, Inc. Methods for treating arenaviridae and coronaviridae virus infections
US11260070B2 (en) 2017-03-14 2022-03-01 Gilead Sciences, Inc. Methods of treating feline coronavirus infections
US11266681B2 (en) 2017-07-11 2022-03-08 Gilead Sciences, Inc. Compositions comprising an RNA polymerase inhibitor and cyclodextrin for treating viral infections
US11491169B2 (en) 2020-05-29 2022-11-08 Gilead Sciences, Inc. Remdesivir treatment methods
US11492353B2 (en) 2010-07-22 2022-11-08 Gilead Sciences, Inc. Methods and compounds for treating Paramyxoviridae virus infections
US11613553B2 (en) 2020-03-12 2023-03-28 Gilead Sciences, Inc. Methods of preparing 1′-cyano nucleosides
US11660307B2 (en) 2020-01-27 2023-05-30 Gilead Sciences, Inc. Methods for treating SARS CoV-2 infections
US11701372B2 (en) 2020-04-06 2023-07-18 Gilead Sciences, Inc. Inhalation formulations of 1'-cyano substituted carba-nucleoside analogs
US11780844B2 (en) 2022-03-02 2023-10-10 Gilead Sciences, Inc. Compounds and methods for treatment of viral infections
US11814406B2 (en) 2020-08-27 2023-11-14 Gilead Sciences, Inc. Compounds and methods for treatment of viral infections
US11939347B2 (en) 2020-06-24 2024-03-26 Gilead Sciences, Inc. 1′-cyano nucleoside analogs and uses thereof
US12030906B2 (en) 2017-05-01 2024-07-09 Gilead Sciences, Inc. Crystalline forms of (s)-2-ethylbutyl 2-(((s)-(((2r,3s,4r,5r)-5-(4-aminopyrrolo[2,1-f] [1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl)methoxy) (phenoxy) phosphoryl)amino)propanoate
US12357577B1 (en) 2024-02-02 2025-07-15 Gilead Sciences, Inc. Pharmaceutical formulations and uses thereof

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5283178B2 (ja) * 2009-03-05 2013-09-04 株式会社島津製作所 マトリックス支援レーザ脱離イオン化質量分析用マトリックス

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08301878A (ja) * 1995-04-28 1996-11-19 Toagosei Co Ltd 三フッ化ホウ素配位化合物およびオリゴヌクレオチドの合成方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08301878A (ja) * 1995-04-28 1996-11-19 Toagosei Co Ltd 三フッ化ホウ素配位化合物およびオリゴヌクレオチドの合成方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BEAUCAGE S L ET AL: "ADVANCES IN THE SYNTHESIS OF OLIGONUCLEOTIDES BY THE PHOSPHORAMIDITE APPROACH", TETRAHEDRON,NL,ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, vol. 48, no. 12, 1992, pages 2223 - 2311, XP000915225, ISSN: 0040-4020 *

Cited By (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10988498B2 (en) 2009-09-21 2021-04-27 Gilead Sciences, Inc. Processes and intermediates for the preparation of 1′-substituted carba-nucleoside analogs
US11492353B2 (en) 2010-07-22 2022-11-08 Gilead Sciences, Inc. Methods and compounds for treating Paramyxoviridae virus infections
CN113549120B (zh) * 2014-10-29 2025-04-29 吉利德科学公司 制备核糖核苷的方法
CN113549120A (zh) * 2014-10-29 2021-10-26 吉利德科学公司 制备核糖核苷的方法
CN107074902A (zh) * 2014-10-29 2017-08-18 吉利德科学公司 制备核糖核苷的方法
US11266666B2 (en) 2014-10-29 2022-03-08 Gilead Sciences, Inc. Methods for treating Filoviridae virus infections
US11344565B2 (en) 2014-10-29 2022-05-31 Gilead Sciences, Inc. Methods for the preparation of ribosides
US11007208B2 (en) 2015-09-16 2021-05-18 Gilead Sciences, Inc. Methods for treating arenaviridae and coronaviridae virus infections
US11382926B2 (en) 2015-09-16 2022-07-12 Gilead Sciences, Inc. Methods for treating Arenaviridae and Coronaviridae virus infections
US11260070B2 (en) 2017-03-14 2022-03-01 Gilead Sciences, Inc. Methods of treating feline coronavirus infections
US12030906B2 (en) 2017-05-01 2024-07-09 Gilead Sciences, Inc. Crystalline forms of (s)-2-ethylbutyl 2-(((s)-(((2r,3s,4r,5r)-5-(4-aminopyrrolo[2,1-f] [1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl)methoxy) (phenoxy) phosphoryl)amino)propanoate
US11266681B2 (en) 2017-07-11 2022-03-08 Gilead Sciences, Inc. Compositions comprising an RNA polymerase inhibitor and cyclodextrin for treating viral infections
US11975017B2 (en) 2017-07-11 2024-05-07 Gilead Sciences, Inc. Compositions comprising an RNA polymerase inhibitor and cyclodextrin for treating viral infections
US11660307B2 (en) 2020-01-27 2023-05-30 Gilead Sciences, Inc. Methods for treating SARS CoV-2 infections
US11613553B2 (en) 2020-03-12 2023-03-28 Gilead Sciences, Inc. Methods of preparing 1′-cyano nucleosides
US12012431B2 (en) 2020-03-12 2024-06-18 Gilead Sciences, Inc. Methods of preparing 1′-cyano nucleosides
US11701372B2 (en) 2020-04-06 2023-07-18 Gilead Sciences, Inc. Inhalation formulations of 1'-cyano substituted carba-nucleoside analogs
US11975012B2 (en) 2020-05-29 2024-05-07 Gilead Sciences, Inc. Remdesivir treatment methods
US11491169B2 (en) 2020-05-29 2022-11-08 Gilead Sciences, Inc. Remdesivir treatment methods
US11903953B2 (en) 2020-05-29 2024-02-20 Gilead Sciences, Inc. Remdesivir treatment methods
US11939347B2 (en) 2020-06-24 2024-03-26 Gilead Sciences, Inc. 1′-cyano nucleoside analogs and uses thereof
US12404289B2 (en) 2020-06-24 2025-09-02 Gilead Sciences, Inc. 1′-cyano nucleoside analogs and uses thereof
US11926645B2 (en) 2020-08-27 2024-03-12 Gilead Sciences, Inc. Compounds and methods for treatment of viral infections
US11814406B2 (en) 2020-08-27 2023-11-14 Gilead Sciences, Inc. Compounds and methods for treatment of viral infections
US12297226B2 (en) 2020-08-27 2025-05-13 Gilead Sciences, Inc. Compounds and methods for treatment of viral infections
US11851438B2 (en) 2022-03-02 2023-12-26 Gilead Sciences, Inc. 1′-cyano nucleoside analogs and methods for treatment of viral infections
US12180217B2 (en) 2022-03-02 2024-12-31 Gilead Sciences, Inc. Compounds and methods for treatment of viral infections
US11780844B2 (en) 2022-03-02 2023-10-10 Gilead Sciences, Inc. Compounds and methods for treatment of viral infections
US11845755B2 (en) 2022-03-02 2023-12-19 Gilead Sciences, Inc. Compounds and methods for treatment of viral infections
US12448383B2 (en) 2022-03-02 2025-10-21 Gilead Sciences, Inc. Compounds and methods for treatment of viral infections
US12357577B1 (en) 2024-02-02 2025-07-15 Gilead Sciences, Inc. Pharmaceutical formulations and uses thereof

Also Published As

Publication number Publication date
MXPA01012444A (es) 2002-07-30
JP2003514766A (ja) 2003-04-22
CA2376016A1 (fr) 2000-12-14
EP1181301A1 (fr) 2002-02-27

Similar Documents

Publication Publication Date Title
US5763599A (en) Nucleoside derivatives with photolabile protective groups
EP1181301A1 (fr) Synthese d'oligonucleotides utilisant des acides de lewis comme activateurs
JP4402454B2 (ja) Ｌｎａホスホラミダイトの製造法
AU651289B2 (en) Process of linking nucleosides with a siloxane bridge
EP0577303B1 (fr) Procédé de glycosylation steréoséléctive
IL106266A (en) Process for the preparation of 2(-o-alkyl guanosine and related compounds
EP1874792A1 (fr) Activateurs destines a la synthese d'oligonucleotides et de phosphoramidites
EP1317466B1 (fr) Synthons destines a la synthese d'oligonucleotides
US5459243A (en) Apparatus and processes for the large scale generation and transfer of diazomethane
CA2254065A1 (fr) Derives de nucleosides a groupes protecteurs photolabiles
WO2020043846A1 (fr) Procédé de préparation de 3'-o-amino-2'-déoxyribonucléoside-5'-triphosphate
US5606049A (en) Method of preparing 2'-O-methyl cytidine monomers useful in oligomer synthesis
US4419509A (en) Process for de-cyanoethylating blocked nucleotides
JP4709959B2 (ja) ヌクレオシドホスホロアミダイト化合物
RU2131880C1 (ru) Способ получения обогащенных бета-аномером нуклеозидов
JP2003513101A (ja) 感光性保護基を有するヌクレオシド誘導体
Pannecouque et al. Synthesis, enzymatic stability and physicochemical properties of oligonucleotides containing a N-cyanoguanidine linkage.
Efimov et al. N-azidomethylbenzoyl blocking group in the phosphotriester synthesis of oligoribonucleotides
CA2362714A1 (fr) Preparation d'arn substitue en position 2'
IE65094B1 (en) A process for the chemical synthesis of oligonucleotides
PL221806B1 (pl) Sposób wprowadzania acetalowych i acetaloestrowych grup ochronnych oraz związki do realizacji tego sposobu
JPH0376319B2 (fr)
EP0075392A1 (fr) Procédé pour la dé-cyanoéthylation de nucléotides bloqués
HK1000535A1 (en) Stereoselective glycosylation process
HK1000535B (en) Stereoselective glycosylation process

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): CA JP MX

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref document number: 2376016

Country of ref document: CA

Ref country code: CA

Ref document number: 2376016

Kind code of ref document: A

Format of ref document f/p: F

Ref country code: JP

Ref document number: 2001 502438

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: PA/a/2001/012444

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2000926516

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000926516

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2000926516

Country of ref document: EP